AIHealthcare

BioIntelliSense is a privately held healthcare technology and medical-device company focused on continuous remote patient monitoring (RPM) and clinical intelligence. Its medical-grade Data-as-a-Service platform combines FDA-cleared BioButton and BioSticker wearable sensors with BioHub gateways, BioMobile applications, BioCloud data services, and BioDashboard software to collect multiparameter vital signs and physiological data from hospital to home. The company uses algorithmic and AI-driven analytics to provide patient trending, exception management, and early-deterioration insights for hospitals, health systems, providers, and virtual-care programs. Its market position is as a specialized clinical RPM provider competing in the broader AI-enabled remote-monitoring market, with differentiation centered on medical-grade continuous monitoring, scalable data services, and partnerships such as Medtronic, Philips, and Hicuity Health. Public sources report conflicting funding totals and round classifications; the most clearly documented recent SEC filing reports approximately $58.05 million sold in a private offering filed in 2025, while older reputable coverage reported a $45 million Series B and approximately $82 million raised to date.